IMPOWER – 022
Infectious Diseases
Sexual and Reproductive Health
A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate the Efficacy and Safety of Oral Islatravir Once-Monthly as Preexposure Prophylaxis in Cisgender Women at High Risk for HIV-1 Infection.
Study Primary Objectives
To evaluate the efficacy of oral ISL QM compared to FTC/TDF QD for the prevention of HIV-1 infection as assessed by the incidence rate per year of confirmed HIV-1 infections. To evaluate the safety and tolerability of oral ISL QM compared to oral FTC/TDF QD as assessed by review of the accumulated safety data.
Study population
Cisgender women (16 – 45 years) at high risk for HIV-1 infection.
Latest Update:
April 2024
For more about IMPOWER – 022 Study forward an email to rhicomms@wrhi.ac.za
